Paper
Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms.
Published May 1, 2005 · Ronald N. Jones, H. Sader, T. Fritsche
Diagnostic microbiology and infectious disease
Q2 SJR score
124
Citations
5
Influential Citations
Abstract
Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
In Vitro Study
Highly CitedStudy Snapshot
Doripenem is a promising, potent carbapenem for parenteral use against Gram-negative bacilli producing various beta-lactamases, with greater enzyme stability compared to ertapenem and imipenem.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...
References
Doripenem versus Pseudomonas aeruginosa In Vitro: Activity against Characterized Isolates, Mutants, and Transconjugants and Resistance Selection Potential
Doripenem is a broad-spectrum parenteral carbapenem with potential for clinical use, but resistance selection is more challenging than other carbapenems.
2004·181citations·S. Mushtaq et al.·Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy
Activities of Doripenem (S-4661) against Drug-Resistant Clinical Pathogens
Doripenem effectively inhibits drug-resistant enteric bacilli, nonfermentative gram-negative bacilli, and penicillin-resistant streptococci, making it a promising new antibiotic for treating resistant infections.
2004·116citations·Ronald N. Jones et al.·Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy
Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
Doripenem is a potent carbapenem with a similar spectrum to current antipseudomonal drugs, but with greater activity against some non-fermentative bacillary strains.
2004·128citations·Ronald N. Jones et al.·The Journal of antimicrobial chemotherapy
The Journal of antimicrobial chemotherapy
Comparative Activities of Doripenem versus Isolates, Mutants, and Transconjugants of Enterobacteriaceae and Acinetobacter spp. with Characterized β-Lactamases
Doripenem is a promising new parenteral carbapenem with similar activity to meropenem and imipenem, but resistance to it may require other mechanisms.
2004·95citations·S. Mushtaq et al.·Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy
Emergence in Klebsiella pneumoniae and Enterobacter cloacae Clinical Isolates of the VIM-4 Metallo-β-Lactamase Encoded by a Conjugative Plasmid
Enterobacteria contribute to the spread of VIM-type enzymes, posing a growing threat to hospital patients receiving carbapenem therapy.
2004·127citations·F. Luzzaro et al.·Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy
Citations
Prevalence and characteristics of ertapenem-mono-resistant isolates among carbapenem-resistant Enterobacterales in China
ETP-mono-resistant CRE strains are relatively prevalent in China, requiring caution when using meropenem alone and prioritizing carbapenemase detection for optimal therapy.
2024·0citations·Yinping Wang et al.·Emerging Microbes & Infections
Emerging Microbes & Infections
Carbapenem resistance in Enterobacterales from agricultural, environmental and clinical origins: South Africa in a global context
Carbapenem resistance in Enterobacterales is increasing globally, with South Africa experiencing recent increases in carbapenemase activity in Enterobacter species and other bacteria.
2023·0citations·Taish Ramkisson et al.·AIMS Microbiology
AIMS Microbiology
An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by Pseudomonas aeruginosa and Acinetobacter baumannii in Critically Ill Adult Patients
Targeted antibiotic therapy for infection-related ventilator-associated complications caused by non-fermenting Gram-negative pathogens should be based on the pathogen's susceptibility pattern and antibiotic dosing optimization.
2021·18citations·Milo Gatti et al.·Antibiotics
Antibiotics
Genetic determinants facilitating the evolution of resistance to carbapenem antibiotics
High-level transposon insertional mutagenesis and a broader spectrum of resistance-conferring mutations contribute to the evolution of carbapenem resistance in Klebsiella pneumoniae, highlighting the need for better antibiotic selection and stewardship.
2021·16citations·Peijun Ma et al.·eLife
eLife
A method to quantify viable carbapenem resistant gram-negative bacteria in treated and untreated wastewater.
Current wastewater treatment technologies effectively reduce carbapenem-resistant bacteria in sewage, with doripenem-supplemented media showing the greatest specificity and selectivity.
2020·10citations·Ryan A Reinke et al.·Journal of microbiological methods
Journal of microbiological methods